ShareValue scores for LENZ: Valuation 59, Quality 37, Growth 66, Health 53.
LENZNASDAQ
LENZ Therapeutics Inc
$5.22
(-0.95%)
LENZNASDAQ
LENZ Therapeutics Inc
$5.22(-0.95%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Weak
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
7% to 18%
Rating
Trap Risk
Return
7% to 18%
Valuation
59
Fair Value
Price vs Value
Quality
37
Weak
Business Strength
Growth
66
Moderate
Revenue & Earnings
Health
53
Moderate
Financial Stability
Momentum
11
Bearish
Price Trend
Company Details
About
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Market Cap$164M
P/E RatioN/A
Dividend YieldNone
Sector Rank#638
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026